CLINICAL TRIALS PROFILE FOR AMINOPHYLLINE DYE FREE

All Clinical Trials for Aminophylline Dye Free

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00130598 ↗	PROVOCATION Trial - PROphylactic intraVenOus Hydration for Contrast Agent Toxicity PreventION	Completed	Swiss National Science Foundation	Phase 2/Phase 3	2005-06-01	Contrast nephropathy (CN) remains a common complication of radiographic procedures and an important cause of hospital-acquired acute renal failure. Only hydration with saline is uniformly accepted and used in clinical practice as a cornerstone for the prevention of CN. But the optimal preventive strategy for CN is not known. Sodium bicarbonate might be even more effective than hydration with sodium chloride for prophylaxis of CN. Therefore the aim of the study is to evaluate the efficacy of two regimens of sodium bicarbonate compared with a prolonged infusion of sodium chloride in the prevention of CN. Primary endpoint: Decrease in glomerular filtration rate (GFR) within 48 hours.
NCT00130598 ↗	PROVOCATION Trial - PROphylactic intraVenOus Hydration for Contrast Agent Toxicity PreventION	Completed	University Hospital, Basel, Switzerland	Phase 2/Phase 3	2005-06-01	Contrast nephropathy (CN) remains a common complication of radiographic procedures and an important cause of hospital-acquired acute renal failure. Only hydration with saline is uniformly accepted and used in clinical practice as a cornerstone for the prevention of CN. But the optimal preventive strategy for CN is not known. Sodium bicarbonate might be even more effective than hydration with sodium chloride for prophylaxis of CN. Therefore the aim of the study is to evaluate the efficacy of two regimens of sodium bicarbonate compared with a prolonged infusion of sodium chloride in the prevention of CN. Primary endpoint: Decrease in glomerular filtration rate (GFR) within 48 hours.
NCT00312273 ↗	Aminophylline in Bradyasystolic Cardiac Arrest	Completed	Heart and Stroke Foundation of Canada	Phase 2	2001-01-01	The purpose of this study is to evaluate the effect of aminophylline in patients with out-of-hospital bradyasystolic cardiac arrest.
NCT00312273 ↗	Aminophylline in Bradyasystolic Cardiac Arrest	Completed	Vancouver Coastal Health Research Institute	Phase 2	2001-01-01	The purpose of this study is to evaluate the effect of aminophylline in patients with out-of-hospital bradyasystolic cardiac arrest.
NCT00312273 ↗	Aminophylline in Bradyasystolic Cardiac Arrest	Completed	Vancouver General Hospital	Phase 2	2001-01-01	The purpose of this study is to evaluate the effect of aminophylline in patients with out-of-hospital bradyasystolic cardiac arrest.
NCT00442338 ↗	Study of MK-0476 in Adult Patients With Acute Asthma (0476-334)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2007-03-01	The study estimates the efficacy and safety of MK0476 and aminophylline intravenous administration in adult participants with acute asthma.

Clinical Trial Conditions for Aminophylline Dye Free

Condition Name

Condition Name for Aminophylline Dye Free
Intervention	Trials
Acute Kidney Injury	5
Aminophylline	3
Chronic Obstructive Pulmonary Disease	2
Post-dural Puncture Headache	2

Condition MeSH

Condition MeSH for Aminophylline Dye Free
Intervention	Trials
Acute Kidney Injury	6
Wounds and Injuries	4
Lung Diseases, Obstructive	3
Altitude Sickness	3

Clinical Trial Locations for Aminophylline Dye Free

Trials by Country

Trials by Country for Aminophylline Dye Free
Location	Trials
United States	13
China	7
Egypt	7
Italy	2
United Kingdom	2

Trials by US State

Trials by US State for Aminophylline Dye Free
Location	Trials
Illinois	3
Colorado	2
North Carolina	2
California	2
Oklahoma	1

Clinical Trial Progress for Aminophylline Dye Free

Clinical Trial Phase

Clinical Trial Phase for Aminophylline Dye Free
Clinical Trial Phase	Trials
Phase 4	12
Phase 3	3
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for Aminophylline Dye Free
Clinical Trial Phase	Trials
Completed	19
Not yet recruiting	9
Unknown status	4

Clinical Trial Sponsors for Aminophylline Dye Free

Sponsor Name

Sponsor Name for Aminophylline Dye Free
Sponsor	Trials
Rush University Medical Center	3
Tanta University	3
Stanford University	2

Sponsor Type

Sponsor Type for Aminophylline Dye Free
Sponsor	Trials
Other	47
U.S. Fed	3
Industry	1

Aminophylline: Clinical Trials, Market Analysis, and Projections

Introduction to Aminophylline

Aminophylline is a methylxanthine derivative used primarily in the treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, and chronic bronchitis. It acts as a bronchodilator, relaxing the muscles in the airways, and is administered both orally and intravenously.

Clinical Uses of Aminophylline

Aminophylline is utilized for several clinical purposes:

• Respiratory Disorders: It is commonly used to treat acute exacerbations of asthma and COPD, as well as other chronic lung diseases. It works as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids[1][4].
• Cardiovascular Applications: Aminophylline can reverse the effects of regadenoson, dipyridamole, or adenosine-based infusions during nuclear cardiology stress testing. It is also used to prevent slow heart rates during complex cardiovascular interventions and to treat heart block due to acute inferior myocardial infarction[1].
• Other Uses: It has been reported to be effective in preventing anaphylactic shock and has shown promise as a body fat reducer when used as a topical cream[1].

Clinical Trials and Research

While there are no recent clinical trials specifically focused on aminophylline itself, the broader context of respiratory disease treatment provides insights into the ongoing research in this area.

• COPD Studies: A study on danirixin, another drug for COPD, highlights the ongoing research into respiratory symptoms and treatment efficacy. This Phase IIb dose-ranging study evaluates the clinical activity and safety of danirixin in participants with COPD, which can provide a framework for understanding the needs and challenges in treating respiratory diseases[3].

Pharmacology and Mechanism of Action

Aminophylline works through two primary mechanisms:

• Phosphodiesterase Inhibition: It is a competitive nonselective phosphodiesterase inhibitor, which raises intracellular cyclic adenosine monophosphate (cAMP) levels. This action activates protein kinase A (PKA), inhibits tumor necrosis factor-alpha (TNF-alpha) and leukotriene synthesis, and reduces inflammation and innate immunity[1].
• Adenosine Receptor Antagonism: Aminophylline is a nonselective adenosine receptor antagonist, which contributes to its bronchodilatory, diuretic, and central nervous system stimulatory effects[1].

Side Effects and Safety

Aminophylline can lead to several side effects, including theophylline toxicity, decreased sedative effects of propofol, and reduced antiseizure action of topiramate. Elderly patients may be more sensitive to its effects, requiring dose adjustments[1][4].

Market Analysis and Projections

Current Market Size

The global aminophylline market was valued at USD 291.2 million in 2023. This market is driven by the widespread use of aminophylline in treating respiratory conditions such as asthma and COPD[5].

Growth Projections

The market is expected to grow at a compound annual growth rate (CAGR) of 2.1% from 2024 to 2032, reaching a projected value of USD 350.2 million by 2032. This growth is attributed to the rising prevalence of respiratory disorders, the increasing demand for cost-effective treatment options, and the preference for oral medications[2][5].

Key Drivers

• Rising Prevalence of Respiratory Disorders: According to the World Health Organization (WHO), respiratory diseases are a major cause of death globally. The increasing number of asthma cases, affecting around 339 million individuals worldwide, highlights the need for effective asthma therapeutics[5].
• Demand for Cost-Effective Treatments: The growing need for affordable treatment options for respiratory diseases is a significant driver for the aminophylline market[2][5].
• Patient Preference for Oral Medications: The preference for oral medications over other forms of administration is also expected to fuel market growth[2].

Challenges and Pitfalls

Despite the growth projections, the aminophylline market faces several challenges:

• Side Effects and Toxicity: The potential for theophylline toxicity and other side effects can limit its use and impact market growth[1].
• Competition from New Therapies: The development of new therapies for respiratory diseases could pose a challenge to the market share of aminophylline[3].

Conclusion

Aminophylline remains a crucial medication in the management of respiratory disorders, particularly asthma and COPD. Its clinical uses are well-established, and ongoing research in respiratory diseases continues to highlight the importance of effective bronchodilators.

Key Takeaways

• Aminophylline is used to treat acute exacerbations of asthma and COPD, as well as other respiratory conditions.
• It works through phosphodiesterase inhibition and adenosine receptor antagonism.
• The global aminophylline market is expected to grow at a CAGR of 2.1% from 2024 to 2032.
• The market is driven by the rising prevalence of respiratory disorders and the demand for cost-effective treatments.
• Side effects and toxicity are significant challenges that need to be managed.

FAQs

What is the primary use of aminophylline?

Aminophylline is primarily used to treat airway obstruction from asthma or COPD.

How is aminophylline administered?

Aminophylline can be administered both orally and intravenously.

What are the key mechanisms of action of aminophylline?

Aminophylline acts as a nonselective phosphodiesterase inhibitor and a nonselective adenosine receptor antagonist.

What are the potential side effects of aminophylline?

Aminophylline can lead to theophylline toxicity, decreased sedative effects of propofol, and reduced antiseizure action of topiramate.

What is the projected growth rate of the aminophylline market?

The global aminophylline market is expected to grow at a CAGR of 2.1% from 2024 to 2032.

What are the main drivers of the aminophylline market growth?

The market growth is driven by the rising prevalence of respiratory disorders, the demand for cost-effective treatments, and the preference for oral medications.

Sources

1. Wikipedia: Aminophylline.
2. Grand View Research: Aminophylline Market Size, Share And Growth Report, 2030.
3. ClinicalTrials.gov: Danirixin Dose Ranging Study in Participants with COPD.
4. Mayo Clinic: Aminophylline (intravenous route).
5. GMI Insights: Aminophylline Market Size.